ND0611 ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	2

6. パーキンソン病

---

臨床試験数 : 2,298 /  薬物数 : 2,202 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01229332 (ClinicalTrials.gov)	January 2011	3/10/2010	A Safety, Tolerability and Pharmacokinetic Study of ND0611 on the Top of Different Oral Dosage Forms of Levodopa/Carbidopa in Parkinson's Disease Patients	A Phase I/II, Single-center, Randomized, Cross-over, Double-blind, Placebo-controlled Study Evaluating Safety, Tolerability and Pharmacokinetic Profile of Levodopa Following Administration of Subcutaneous Continuously-delivered Carbidopa Solution (ND0611) on the Top of Different Oral Dosage Forms of Levodopa/Carbidopa in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations	Parkinson's Disease	Drug: Saline;Drug: Carbidopa	NeuroDerm Ltd.	NULL	Completed	30 Years	N/A	Both	24	Phase 1/Phase 2	Israel
2	NCT01103011 (ClinicalTrials.gov)	April 2010	12/4/2010	Safety, Tolerability and Pharmacokinetic Profile of Levodopa Administered With Continuous Administration of ND0611	A Phase I, Single Center, Blinded, Controlled Study Evaluating Safety, Tolerability and Pharmacokinetic Profile of Levodopa Following Repeated Administration of Oral Levodopa/Carbidopa and Continuously Delivered ND0611	Parkinson's Disease	Drug: ND0611	NeuroDerm Ltd.	NULL	Completed	18 Years	50 Years	Male	8	Phase 1	Israel